Navigation Links
Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Date:5/10/2011

HOUSTON A new genomic test combining multiple signatures a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

The findings, published in the May 11 issue of JAMA, also may determine those for whom standard therapy alone might not offer enough, and/or for whom an appropriate clinical trial in the adjuvant setting could provide additional benefit.

"The research builds on a decade of collaborative work in developing a clinically meaningful chemotherapy predictor, and, if validated in future studies, could guide therapy for about 80 percent of newly diagnosed women with invasive breast cancer who are candidates for chemotherapy," says W. Fraser Symmans, MD, professor in MD Anderson's Department of Pathology.

"The test helps us understand both resistance and response to chemotherapy more specifically, how sensitivity to endocrine therapy would impact a predictor and how to focus on specific subtypes of breast cancer in this case HER2 negative disease stratified by estrogen receptor (ER) status because we've learned that they are so intrinsically different," Symmans continues.

The multicenter study enrolled 310 Stage II and III newly diagnosed women with invasive breast cancer (discovery cohort). All were Her2 negative and received the chemotherapy regimen of sequential taxane and anthracycline, followed by endocrine therapy, if hormone receptor positive. Gene expression microarrays from the discovery cohort were used to develop different predictive signatures for drug resistance and response. Using the signatures for endocrine therapy response, chemotherapy resistance and sensitivity, in combination with other genomic predictors to chemotherapy response, breast cancer treatm
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
2. New genomics research investigates metastatic childhood cancers
3. Promise of genomics research needs a realistic view
4. NHGRI charts course for the next phase of genomics research
5. Tufts University calls for moderate approach to teaching personalized genomic testing
6. Genomic markers may head off thousands of thyroid surgeries
7. Forces for cancer spread: Genomic instability and evolutionary selection
8. Genomic Systems announces moratorium on studying and treating terminal cancer has ended
9. La Jolla Institute to develop San Diegos first center for RNAi genomics research
10. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
11. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... products at the same rate as adults in the ... Center for Healthy Neighborhoods (PRCHN) at Case Western Reserve ... in five high school students, report use of any ... surprising is that ninth- through twelfth- graders are smoking ... matching a national trend. More students report cigar ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay ... program for the poor, visit the emergency room for medical ... a U.S. survey finds. And kids with Medicaid were ... a reason other than a serious medical problem, according to ... Control and Prevention. Reliance on ER care ...
(Date:7/24/2014)... - Aristotle said, "Love is composed of a single ... that you and your partner were made in heaven ... new study. , Psychologists observe that people talk ... underlying such diversity are some common themes that frame ... frame considers love as perfect unity ("made for each ...
(Date:7/24/2014)... The South American air and missile defense radar market ... expected to register a CAGR of 9.64% to reach $340 ... security issues like drug trafficking. Brazil is the only market ... and missile defense radar market. This is followed by Argentina ... for radar systems in terms of costal surveillance and other ...
(Date:7/24/2014)... 2014 Dr. Kwame Bawuah Edusei, a ... with an admonition to the youth to persevere in ... He also advised the youth to stay away from ... said, “This workshop will afford you the opportunity of ... withstand the storms in your career path.” Professionals in ...
Breaking Medicine News(10 mins):Health News:Cuyahoga County high school students smoking at the same rate as adults 2Health News:Cuyahoga County high school students smoking at the same rate as adults 3Health News:Cuyahoga County high school students smoking at the same rate as adults 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:New research: When it hurts to think we were made for each other 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... March 17 Researchers will unveil a,new ... been shown in numerous,published studies to help ... the performance of daily living tasks essential ... Corporation, a San,Francisco-based neuroscience company, will introduce ...
... is the Largest Prospective Trial to Examine Asthma Outcomes Based on ... ... N.C. and PHILADELPHIA, March 16 ,Data presented today by GlaxoSmithKline showed ... in asthma patients did not,lead to different responses to Advair Diskus(R) ...
... is the daily,"Profile America" feature from the U.S. Census ... Profile America -- Saturday, March 15th. If you,re ... it,s time to pause,stand back and reflect that there ... events celebrating the value of laughter and those who ...
... Coronary Heart Disease, WASHINGTON, March 14 ... the decision by the Centers,for Medicare and Medicaid ... coverage,for cardiac computed tomographic angiography (CTA) for the ... its national coverage decision for this important,tool for ...
... (March 13, 2008) The American Academy of Cosmetic ... its 2007 Procedural Data. This information is collected by ... that sclerotherapy, the standard treatment for spider and varicose ... surgical procedure, due in large part to men. ...
... found it made difference when disease moved from colon, ... certain patients with cancer that has spread to the ... surgery combined with a special kind of chemotherapy can ... The findings are from one of two Wake Forest ...
Cached Medicine News:Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 2Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 4Health News:SCAI Applauds CMS Decision to Continue Coverage of Cardiac CT Scans 2Health News:Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining 2
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
(Date:7/24/2014)... , July 24, 2014 Talyst, a ... the 2014 National Association of State Veterans Homes (NASVH) ... . The goal of the NASVH is to ensure ... benefits, services, long term health care and respect which ... With the InSite® Remote Dispensing System, Talyst ...
(Date:7/24/2014)... July 24, 2014  Lazarus Effect, a medical ... interventional devices to facilitate removal of blood clots, ... Trademark Office has issued a new patent (U.S. ... company,s Lazarus Cover TM and ReCover TM ... is a single-component stent-retriever (stentriever) with an integrated, ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
1 mm wide by 28 mm long sterling silver blade. Flat serrated handle with polished finish....
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Serrated rake tip spatula with 20 gauge shaft. Black finish for reduced glare. Can be used with 20 gauge MVR blades....
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Medicine Products: